JPMorgan lowered the firm’s price target on 10x Genomics (TXG) to $9 from $12 and keeps a Neutral rating on the shares post the Q1 report. The firm is constructive on 10x’s positioning in single cell and spatial, but says the limited visibility in U.S. academic spending gives it pause as does the impact of the recent commercial reorg on Xenium placement improvement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics: Navigating Uncertainty Amidst Regional Variations and Budget Constraints
- 10x Genomics: Hold Rating Amidst Research Funding Uncertainty and Market Risks
- 10x Genomics Reports Q1 2025 Financial Results
- 10x Genomics: Hold Rating Amid Uncertain Outlook and Strategic Cost Management
- 10x Genomics Announces Workforce Reduction to Cut Costs